Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In...

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Gene therapy for cancer requires selectivity for cancer cells and non-toxicity to normal cells.
• Existing p53-based therapies can be toxic to normal cells and may increase chemotherapy resistance.

Purpose of the Study:

• To design a novel gene therapy construct with enhanced selectivity and efficacy against cancer cells.
• To develop a promoter system that is activated only in cancer cells with specific mutations (mutant Ras and mutant p53).

Main Methods:

• A minimal p14^ARF promoter (p14^ARFmin) was engineered with specific enhancer and inhibitory elements.
• The modified promoter was linked to bicistronic P14 and truncated BID (tBID) genes.
• The construct's activation was designed to be dependent on mutant Ras and inhibited by wild-type p53.

Main Results:

• The p14^ARFmin promoter demonstrated preferential activation in cells with mutant Ras and mutant p53.
• The P14-tBID gene combination synergistically induced apoptosis via intrinsic and extrinsic pathways.
• The construct showed bidirectional promoter control, repressed by wild-type p53 and activated in cancer cells with specific mutations.

Conclusions:

• The novel p14^ARFmin-P14-tBID construct offers a selective gene therapy approach for cancers with Ras and p53 mutations.
• This strategy avoids toxicity to normal cells and does not induce chemoresistance-associated cell cycle arrest.
• The synergistic induction of apoptosis presents a potent therapeutic potential for targeted cancer treatment.